Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody produced by suspension culture of mammalian cells (Chinese hamster ovary cells) in a sterile culture medium. The purification process includes specific virus inactivation and removal steps using affinity chromatography and ion exchange. M...
which targets the CD30 antigen found on lymphocytes, combined with a chemotherapy drug called MMAE. Ado-trastuzumab emtansine (Kadcyla or TDM-1) is another example, targeting the HER2 protein and linked to
Trastuzumab is typically used as part of a treatment course that includes chemotherapy. Pertuzumab (Perjeta) is another antibody to HER2 that is also used in breast cancer treatment. It binds to a different part of the HER2 receptor than trastuzumab, but triggers a similar response. In some ...
C. Hudis, C. Swanton, Y.Y. Janjigian, et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors Breast Cancer Research, 15 (2013), p. R110 doi:10.1186/bcr3577 View in ScopusGoogle Scholar 100...
that contain active receptors for the protein known as 'human epidermal growth factor 2' (HER2). Such tumours can be treated by the drug trastuzumab (marketed as Herceptin). This is believed to be the first time a specific genetic risk factor for HER2 positive breast tumours has been found....
et al. IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget 8, 2731–2744 (2017). Article PubMed Google Scholar Evren, E. et al. Distinct developmental pathways from blood monocytes generate...
44,45 A common adverse effect is a severe generalised acneiform eruption.46 Panitumumab, another EGFR competitor, has an FDA box warning for severe dermatologic toxicities.47 Trastuzumab, a humanised monoclonal antibody targeting the extracellular domain of the HER-2/neu protein and used to control ...
Trastuzumab (Herceptin) is a human epidermal growth factor receptor two (HER2) binding site-targeting monoclonal antibody that inhibits the development of cancer cells. Immunogenic trastuzumab-binding peptides (TBP) can stimulate the body to make antibodies that block the development of HER2-positive ...
Cancer, also known as malignant tumour or neoplasm, is a leading cause of death worldwide. One distinct feature from normal cells is that cancerous cells often overexpress protein on the cell membrane—for instance, the overexpression of human epidermal growth factor receptor 2. The expression of...